Parliamentary probe finds racism evidence in NHS sickle cell carePatients with sickle cell disease are facing racism in the NHS that is putting their lives a risk, Share XParliamentary probe finds racism evidence in NHS sickle cell carehttps://pharmaphorum.com/news/parliamentary-probe-finds-racism-evidence-in-nhs-sickle-cell-care/
Silence Tx uses game to raise thalassaemia awarenessUK biotech Silence Therapeutics has launched an online game to raise the profile of the rare blood disorder Share XSilence Tx uses game to raise thalassaemia awarenesshttps://pharmaphorum.com/news/silence-tx-uses-game-to-raise-thalassaemia-awareness/
bluebird offers instalment payments for Zynteglo gene therapybluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with Share Xbluebird offers instalment payments for Zynteglo gene therapyhttps://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
Celgene gets speedy review for thalassaemia drug luspaterceptIt’s shaping up to be a landmark year for the community of patients with rare blood disorder beta Share XCelgene gets speedy review for thalassaemia drug luspatercepthttps://pharmaphorum.com/news/celgene-gets-speedy-review-for-thalassaemia-drug-luspatercept/
